COLL
Price
$23.20
Change
+$0.69 (+3.07%)
Updated
Oct 15, 04:59 PM (EDT)
Capitalization
736.73M
21 days until earnings call
Intraday BUY SELL Signals
TEVA
Price
$41.12
Change
+$0.40 (+0.98%)
Updated
Oct 15, 04:59 PM (EDT)
Capitalization
46.11B
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COLL vs TEVA

COLL vs TEVA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COLL vs. TEVA commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and TEVA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for COLL with price predictions
Oct 14, 2026

COLL's RSI Oscillator ascending out of oversold territory

The RSI Indicator for COLL moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 20 of the 26 cases the stock moved higher. This puts the odds of a move higher at 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 53 cases where COLL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on COLL as a result. In 62 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for COLL just turned positive on September 16, 2026. Looking at past instances where COLL's MACD turned positive, the stock continued to rise in 20 of 34 cases over the following month. The odds of a continued upward trend are 59%.

Following a +1.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where COLL advanced for three days, in 217 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COLL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for COLL entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.362) is normal, around the industry mean (43.873). P/E Ratio (17.819) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.664) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.995) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. COLL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COLL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for TEVA with price predictions
Oct 14, 2026

TEVA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for TEVA turned positive on October 12, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on TEVA as a result. In 60 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 226 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 208 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.848) is normal, around the industry mean (43.873). P/E Ratio (64.800) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
COLL vs TEVA: Fundamental Ratings
COLL
TEVA
OUTLOOK RATING
1..100
3536
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
927
SMR RATING
1..100
5072
PRICE GROWTH RATING
1..100
8136
P/E GROWTH RATING
1..100
8811
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (63) in the Pharmaceuticals Other industry is in the same range as TEVA (70) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (7) in the Pharmaceuticals Generic industry is significantly better than the same rating for COLL (92) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than COLL’s over the last 12 months.

COLL's SMR Rating (50) in the Pharmaceuticals Other industry is in the same range as TEVA (72) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Price Growth Rating (36) in the Pharmaceuticals Generic industry is somewhat better than the same rating for COLL (81) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than COLL’s over the last 12 months.

TEVA's P/E Growth Rating (11) in the Pharmaceuticals Generic industry is significantly better than the same rating for COLL (88) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLTEVA
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
64%
Momentum
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 8 days ago
69%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 15 days ago
68%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
74%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (COLL: $22.51 vs. TEVA: $40.72)
Brand notoriety: COLL: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 106% vs. TEVA: 184%
Market capitalization -- COLL: $736.73M vs. TEVA: $46.11B
COLL [@Pharmaceuticals: Generic] is valued at $736.73M. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $46.11B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 0 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).

  • COLL’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 2 green, 3 red.
According to our system of comparison, TEVA is a better buy in the long-term than COLL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).

  • COLL’s TA Score: 5 bullish, 2 bearish.
  • TEVA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, COLL is a better buy in the short-term than TEVA.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а +2.64% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +3.93% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.15%. For the same industry, the average monthly price growth was -2.27%, and the average quarterly price growth was +12.49%.

Reported Earning Dates

COLL is expected to report earnings on Nov 05, 2026.

TEVA is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
COLL
Daily Signal:
Gain/Loss:
TEVA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BRO64.800.75
+1.17%
Brown & Brown
OXSQ1.34N/A
N/A
Oxford Square Capital Corp
LXU10.10-0.13
-1.27%
LSB Industries
BIYA1.39-0.08
-5.44%
Baiya International Group Inc.
WSC16.19-1.10
-6.36%
WillScot Holdings Corporation

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-1.28%
AMRX - TEVA
39%
Loosely correlated
-3.42%
VTRS - TEVA
33%
Loosely correlated
+1.10%
COLL - TEVA
28%
Poorly correlated
+4.55%
HROW - TEVA
26%
Poorly correlated
-3.54%
SNDL - TEVA
26%
Poorly correlated
-0.86%
More